Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03883113
Recruitment Status : Active, not recruiting
First Posted : March 20, 2019
Last Update Posted : October 30, 2019
Sponsor:
Information provided by (Responsible Party):
Vaccitech Limited

Brief Summary:
A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.

Condition or disease Intervention/treatment Phase
Influenza Biological: MVA-NP+M1 Biological: Saline Biological: H3N2 (A/Belgium/2417/2015) Phase 2

Detailed Description:
The study consists of an outpatient vaccination phase (155 participants), and at least 2 months later an inpatient challenge phase (134 participants). Participants are randomized 93:62 to receive either MVA-NP+M1 or Placebo. Up to 20 participants will be challenged over several 3-week blocks, and the remainder at the final 3-week block for a total of 80 MVA-NP+M1 and 54 Placebo recipients challenged.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 155 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
Actual Study Start Date : June 3, 2019
Estimated Primary Completion Date : December 16, 2019
Estimated Study Completion Date : March 17, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: MVA-NP+M1 & H3N2 Challenge Virus
Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
Biological: MVA-NP+M1
Trial Vaccine

Biological: H3N2 (A/Belgium/2417/2015)
Challenge Agent

Placebo Comparator: Saline Placebo & H3N2 Challenge Virus
Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
Biological: Saline
Sodium Chloride Placebo

Biological: H3N2 (A/Belgium/2417/2015)
Challenge Agent




Primary Outcome Measures :
  1. Degree of viral shedding [ Time Frame: 9 days ]
    Measure of nasopharyngeal viral shedding during challenge; recorded as viral AUC as determined by qPCR


Secondary Outcome Measures :
  1. Incidence of laboratory-confirmed influenza-like illness [ Time Frame: 9 days ]
    Incidence of laboratory-confirmed influenza-like illness time to start; time to peak and duration of qPCR and/or QCulture

  2. Attack rate of challenge agent [ Time Frame: 9 days ]
    The attack rate, defined as percentage of inoculated participants with at least two consecutive positive swabs as determined by qPCR

  3. Self-reported Influenza symptom scores [ Time Frame: 11 days ]
    Total AUC for total symptom scores measured by questionnaires (regardless of take rate) for MVA-NP+M1 vs. Placebo

  4. Total days of fever [ Time Frame: 11 days ]
    Total days of fever for MVA-NP+M1 vs. Placebo

  5. Total mucus weight [ Time Frame: 11 days ]
    Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo

  6. T Cell responses as defined by ELISpot assay [ Time Frame: 3 months ]
    Correlation of T cell responses to the primary endpoint, symptom scores, and influenza incidence

  7. Safety of MVA-NP+M1 vaccination measured by self-reported symptoms [ Time Frame: 7 days ]
    Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries

  8. Safety of H3N2 challenge in the setting of MVA-NP+M1 vaccination measured by self-reported symptoms and adverse event monitoring [ Time Frame: 17 days ]
    Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring


Other Outcome Measures:
  1. Severity of individual symptoms for MVA-NP+M1 vs. Placebo [ Time Frame: 11 days ]
    Severity of individual self-reported symptoms for MVA-NP+M1 vs. Placebo

  2. Total symptom score time to start, time to peak and duration [ Time Frame: 11 days ]
    Time to start; time to peak and duration of total self-reported symptom score, regardless of take rate

  3. Correlation of T Cell phenotypes with illness outcomes [ Time Frame: 3 months ]
    Correlation of antigen specific T Cell phenotypes with illness outcomes

  4. Vaccination effect on antibody responses by ELISpot and ICS assays [ Time Frame: 3 months ]
    Antibody responses of MVA-NP+M1 vs Placebo following influenza challenge measured by ELISpot and ICS



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males and females aged ≥18 and ≤55 years of age at the point of enrolment.
  • Non-smokers or those who stopped smoking ≥ 3 months prior to screening 1 visit.
  • Willingness to remain in isolation for the duration of the study.
  • A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:

    1. Of non-childbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year).
    2. Of childbearing potential but has been and agrees to continue practicing highly effective contraception or abstinence (if this is the preferred and usual lifestyle of the participant) from 6 months prior to vaccination to 6 months after administration of the influenza challenge virus. Highly effective methods of contraception include 1 or more of the following:

    i. male partner who is sterile (vasectomised) prior to the female participants entry into the study and is the sole sexual partner for the female participant; ii. hormonal (oral, intravaginal, transdermal, implantable or injectable); iii. an intrauterine hormone-releasing system (IUS); iv. an intrauterine device (IUD) with a documented failure rate of < 1%; v. bilateral tubal occlusion.

  • Pre-challenge serum MNT against A/Belgium/4217/2015 (H3N2) challenge strain < 20.

Exclusion Criteria:

  • BMI < 19 and > 32.
  • Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness including a history of chronic respiratory illness.
  • History of seasonal hay fever or a clinically significant seasonal allergic rhinitis (SAR), including the use of symptomatic prescription only medication and non-prescription medication.
  • History or evidence of autoimmune disease or known immunodeficiency of any cause - with the exception of atopic dermatitis/eczema and atopic rhinitis.
  • Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine.
  • History of lung disease (Asthma, COPD).
  • Current smokers or those who stopped smoking < 3months prior to screening 1 visit.
  • Positive diagnostic tests for HIV, Hepatitis B or Hepatitis C indicating active infection.
  • Evidence of drug abuse or a positive urine drug screen or alcohol breath test.
  • Chronic use of any medication or other product (prescription or over-the-counter), for symptoms of rhinitis or nasal congestion or for any chronic nasopharyngeal complaint, or chronic use of any intranasal medication for any indication that has not cessed within 30 days prior to screening 1.
  • Receipt of any investigational drug within 3 months prior to vaccination, or prior participation in a clinical trial of any influenza vaccine, or any investigational vaccine or experimental influenza viral challenge delivered directly to the respiratory tract within 1 year prior to challenge.
  • Receipt of the 2018/2019 seasonal flu vaccine.
  • Receipt of any live vaccines within the 4 weeks prior to vaccination.
  • Any laboratory test which is abnormal and which is deemed by the Investigator(s) to be clinically significant.
  • Receipt of any systemic chemotherapy agent at any time.
  • Physician reported influenza or a syndrome consistent with influenza (as judged by the investigator) in the previous 6 months.
  • Known allergy to treatments for influenza (including but not limited to oseltamivir).
  • History of frequent epistaxis (nose bleeds).
  • Any nasal or sinus surgery within 6 months of Viral Challenge or any significant abnormality, either of which results in alteration of the anatomy of the nose or nasopharynx (including significant nasal polyps).
  • Volunteers with household contacts who are at risk for serious or severe complications of influenza disease including, but not limited to: persons ≥ 65 years; presence of significant chronic cardiopulmonary, metabolic, renal, or neurological conditions; immunosuppression due to any condition or therapies; BMI >40.
  • Participants that are an employee or family member of the Investigator or study site personnel may not be enrolled.
  • Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study.

EXCLUSION (CHALLENGE PERIOD ONLY)

  • Abnormal spirometry assessed to be clinically significant.
  • Known close contact with anyone known to have influenza in the past 7 days at the time of quarantine.
  • ILI symptoms as assessed at the admission to clinic on Day -2 prior to challenge.
  • Presence of fever, defined as participant presenting with a temperature reading of > 38.0°C on admission to quarantine.
  • Qualitative PCR results positive for viral infection. However, participants may be included into later challenge cohort.
  • Acute use of any medication or other product, prescription or over-the-counter, for symptoms of rhinitis or nasal congestion within 7 days prior to challenge. This includes any oral corticosteroid or beta agonist containing nasal spray.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03883113


Locations
Layout table for location information
Belgium
SGS Life Sciences, Clinical Pharmacology Unit (CPU)
Antwerp, Belgium, 2060
Sponsors and Collaborators
Vaccitech Limited
Investigators
Layout table for investigator information
Principal Investigator: Robin Rogiers, MD SGS S.A.

Layout table for additonal information
Responsible Party: Vaccitech Limited
ClinicalTrials.gov Identifier: NCT03883113     History of Changes
Other Study ID Numbers: FLU010
First Posted: March 20, 2019    Key Record Dates
Last Update Posted: October 30, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases